Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Long-Acting Antipsychotic Sampling Program In Hospitals Cleared By OIG Advisory Opinion

Executive Summary

Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.

You may also be interested in...



Free Eye Drops Distribution To Mitigate Drug Side Effects Cleared By HHS OIG

Program relies on a third-party vendor managing a Risk Evaluation and Mitigation Strategy associated with the drug to facilitate delivery of eye drops to patients.

OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs

US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.

HHS IG Calls On Drug Makers To Heed Marketing Laws After Report On Rampant Inappropriate Use Of Atypical Antipsychotics In Medicare

HHS Inspector General finds 88% of Medicare claims for atypical antipsychotic drugs for elderly nursing home residents were used in patients with dementia, despite strict warnings in product labeling.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel